Knight Therapeutics Inc.
KHTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $504 | $552 | $591 | $655 |
| - Cash | $80 | $59 | $72 | $86 |
| + Debt | $49 | $69 | $78 | $41 |
| Enterprise Value | $473 | $562 | $597 | $610 |
| Revenue | $371 | $328 | $294 | $243 |
| % Growth | 13.1% | 11.8% | 20.6% | – |
| Gross Profit | $174 | $153 | $138 | $115 |
| % Margin | 47% | 46.5% | 47% | 47.4% |
| EBITDA | $64 | $41 | $25 | $43 |
| % Margin | 17.3% | 12.5% | 8.6% | 17.5% |
| Net Income | $4 | -$17 | -$30 | $16 |
| % Margin | 1.2% | -5.1% | -10.2% | 6.4% |
| EPS Diluted | 0.043 | -0.16 | -0.26 | 0.13 |
| % Growth | 126.8% | 38.5% | -300% | – |
| Operating Cash Flow | $36 | $36 | $40 | $45 |
| Capital Expenditures | -$31 | -$10 | -$26 | -$224 |
| Free Cash Flow | $5 | $26 | $15 | -$180 |